Biovie presents trial data showing that bezisterim eases movement and daily symptoms in early Parkinson's

Biopharmaceutical company BioVie has presented results from a twelve week study of an experimental tablet called bezisterim at the American Neurological Association meeting in October 2026. Rather than replacing dopamine like standard treatments, bezisterim crosses into the brain to reduce inflammation and help cells use energy more effectively, without suppressing the wider immune system. The trial involved fifty seven people in the early stages of Parkinson's who were not yet taking levodopa. For three months, half took twenty milligrams of bezisterim twice daily, while the other half took a placebo. Assessments were carried out either in clinics or at home by visiting study nurses supervised by specialists over video. Across the whole group, twenty five percent of those taking bezisterim saw a meaningful improvement in an overall measure of movement, sleep, and daily tasks, compared to four percent on the placebo. The tablet also helped prevent decline. Only fourteen percent of the bezisterim group experienced a noticeable worsening of symptoms over the twelve weeks, compared to forty six percent of the placebo group. The strongest results appeared in participants who started the study with higher levels of background inflammation, identified through elevated platelet counts in their blood. Making up roughly half of the trial, these individuals showed clear improvements in both physical movement and non motor symptoms such as fatigue, sleep, mood, and thinking, while those on the placebo saw their scores decline. Blood tests also confirmed reduced inflammation and better cellular health in the active group. Addressing both physical movement and invisible symptoms like fatigue with a single tablet is significant, as non motor issues often go untreated. The medication was well tolerated with no severe side effects, and fewer minor side effects were reported in the bezisterim group than in the placebo group. Because fifty seven people over twelve weeks is a small, early study, BioVie is now using these results to design a larger Phase 3 trial to test if the drug can reliably slow the progression of the condition over the long term.